Protara Therapeutics, Inc. income statement TARA

Annual Quarterly

It recorded a net loss of $57.4 million. Diluted earnings per share were -$1.34.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Research and development
43
+34.5%
32
+26.9%
25
+48.7%
17
-20.3%
21
+76.0%
12
+209.0%
4
-67.3%
12
-45.4%
22
+14.9%
19
+52.4%
Selling, general and administrative
22
+25.6%
17
-6.3%
19
-10.2%
21
-21.5%
26
+17.5%
22
+468.4%
4
-58.5%
10
+9.8%
9
-11.8%
10
+15.9%
Operating income
-65
-31.3%
-49
-12.7%
-44
+35.0%
-67
-41.2%
-47
-37.9%
-34
-339.9%
-8
+63.4%
-21
+29.6%
-30
-5.8%
-29
-37.5%
Pretax income
57
—
—
—
—
—
-15
+27.7%
-21
+30.8%
-30
-5.0%
-29
Net income
-57
-28.8%
-45
-10.3%
-40
+38.7%
-66
-39.6%
-47
-39.1%
-34
-333.9%
-8
+62.2%
-21
+30.8%
-30
-5.0%
-29
-33.4%
Basic EPS
-1.34
+38.2%
-2.17
+39.2%
-3.57
+39.1%
-5.86
—
—
—
—
—
—
Diluted EPS
-1.34
+38.2%
-2.17
+39.2%
-3.57
+39.1%
-5.86
—
—
—
—
—
—
Weighted average shares, basic
43
+108.0%
21
+81.7%
11
—
—
—
—
—
—
—
Weighted average shares, diluted
43
+108.0%
21
+81.7%
11
+0.6%
11
—
—
—
—
—
—
Other measures
Depreciation and amortization
0
+9.0%
0
-2.6%
0
+37.5%
0
+112.0%
0
+13.6%
0
+543.8%
0
-86.1%
0
-22.3%
0
+20.3%
0
+115.8%
EBITDA
-64
-31.5%
-49
-12.8%
-43
+35.2%
-67
-41.0%
-47
-37.9%
-34
-339.5%
-8
+63.2%
-21
+29.6%
-30
-5.7%
-29
-37.3%
Interest coverage
—
—
—
—
—
-1,013.06x
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. More on our methodology.

New to this? Read How to Read an Income Statement, With a Real Example.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
TARA (Nasdaq)
Fiscal year ends
December 31
Headquarters
New York, NY
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1359931
Former names
Protara Therapeutics, Inc. (until Aug 13, 2026); ArTara Therapeutics, Inc. (until Apr 23, 2020); PROTEON THERAPEUTICS INC (until Dec 31, 2019)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.